Lyra Therapeutics, Inc.(LYRA)Earnings, Financials & Key Ratios
LYRA•NASDAQ
$0.44
$781126 mkt cap·Price updated May 1, 2026
AboutLyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.Show more
- Revenue$2M-1.5%
- EBITDA-$96M-43.4%
- Net Income-$93M-49.1%
- EPS (Diluted)-1.43-13.5%
- Gross Margin100%
- EBITDA Margin-6250.13%-45.7%
- Operating Margin-6280.83%-45.8%
- Net Margin-6090.94%-51.4%
- ROE-184.99%-151.1%
- ROIC-145.47%-111.4%
- Debt/Equity2.97+886.4%
LYRA Key Insights
Lyra Therapeutics, Inc. (LYRA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗High debt to equity ratio of 3.0x
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 1 (bottom 1%)
- ✗Shares diluted 30.7% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
LYRA Price & Volume
Lyra Therapeutics, Inc. (LYRA) stock price & volume — 10-year historical chart
Loading chart...
LYRA Growth Metrics
Lyra Therapeutics, Inc. (LYRA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years75.25%
TTM-59.21%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM66.25%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-508.61%
Return on Capital
10 Years-73.67%
5 Years-77.01%
3 Years-85.24%
Last Year-109.04%
LYRA Peer Comparison
Lyra Therapeutics, Inc. (LYRA) competitors in Drug Delivery Technology Platforms — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 XNCR | 902.8M | 12.31 | -9.93 | 13.65% | -185.71% | -23.68% | 0.30 | |
 PRAX | 9.63B | 333.28 | -24.72 | -100% | -43.02% | 0.00 | ||
 SINT | 8.64M | 2.39 | -0.39 | -18.3% | -13.59% | -367.21% | 1.11 | |
 ARWR | 10.92B | 77.95 | -6389.34 | 232.58% | -48.38% | -55.47% | 0.73 | |
 MCRB | 74.36M | 7.72 | 12.06 | -40.89% | -127.3% | 1.88 | ||
 NKTR | 1.69B | 83.37 | -8.57 | -43.89% | -297.07% | -399.1% | 1.66 | |
 AGIO | 1.64B | 27.53 | -3.87 | 48.03% | -6.4% | -34.11% | 0.05 | |
 ACRS | 585.63M | 4.86 | -9.17 | -58.19% | -8.3% | -62.98% |
Compare LYRA vs Peers
Lyra Therapeutics, Inc. (LYRA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
LYRA Income Statement
Lyra Therapeutics, Inc. (LYRA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 1.24M | 0 | 0 | 285K | 1.36M | 1.56M | 1.53M | 600K |
| Revenue Growth % | - | -100% | - | - | 378.25% | 14.31% | -1.54% | -59.21% |
| Cost of Goods Sold | 0 | 0 | 12.52M | 29.69M | 0 | 0 | 0 | 300K |
| COGS % of Revenue | - | - | - | 10418.95% | - | - | - | - |
| Gross Profit | 1.24M▲ 0% | 0▼ 100.0% | -12.52M▲ 0% | -29.41M▼ 134.9% | 1.36M▲ 104.6% | 1.56M▲ 14.3% | 1.53M▼ 1.5% | 300K▲ 0% |
| Gross Margin % | 100% | - | - | -10318.95% | 100% | 100% | 100% | 50% |
| Gross Profit Growth % | - | -100% | - | -134.86% | 104.63% | 14.31% | -1.54% | - |
| Operating Expenses | 8.5M | 16.52M | 9.69M | 14.21M | 57.67M | 68.68M | 97.88M | 35.23M |
| OpEx % of Revenue | 683.52% | - | - | 4984.56% | 4231.03% | 4408.09% | 6380.83% | - |
| Selling, General & Admin | 3.53M | 4.49M | 9.69M | 14.21M | 17.56M | 19.06M | 18.5M | 12.51M |
| SG&A % of Revenue | 283.6% | - | - | 4984.56% | 1288.04% | 1223.17% | 1206.06% | - |
| Research & Development | 4.97M | 12.03M | 12.52M | 29.69M | 38.8M | 48.03M | 43.77M | 20.39M |
| R&D % of Revenue | 399.92% | - | - | 10418.95% | 2846.44% | 3082.73% | 2853.06% | - |
| Other Operating Expenses | 0 | -1 | -12.52M | -29.69M | 1.32M | 1.59M | 35.62M | 1.68M |
| Operating Income | -7.26M▲ 0% | -16.52M▼ 127.6% | -22.21M▼ 34.4% | -43.62M▼ 96.4% | -56.31M▼ 29.1% | -67.12M▼ 19.2% | -96.35M▼ 43.5% | -34.94M▲ 0% |
| Operating Margin % | -583.52% | - | - | -15303.51% | -4131.03% | -4308.09% | -6280.83% | -5822.5% |
| Operating Income Growth % | - | -127.57% | -34.45% | -96.38% | -29.1% | -19.21% | -43.55% | - |
| EBITDA | -7.18M | -16.49M | -22.11M | -42.61M | -55.24M | -66.84M | -95.88M | -34.36M |
| EBITDA Margin % | -576.93% | - | - | -14952.28% | -4052.75% | -4290.24% | -6250.13% | -5726% |
| EBITDA Growth % | - | -129.79% | -34.09% | -92.7% | -29.63% | -21.01% | -43.44% | 65.99% |
| D&A (Non-Cash Add-back) | 82K | 27K | 95K | 1M | 1.07M | 278K | 471K | 579K |
| EBIT | -7.26M | -16.52M | -22.21M | -43.62M | -54.99M | -65.53M | -60.73M | -31.14M |
| Net Interest Income | 36K | 213K | 82K | 102K | 1.04M | 4.5M | 2.95M | 1.4M |
| Interest Income | 36K | 213K | 82K | 102K | 1.04M | 4.5M | 2.95M | 1.4M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 1.23M | 213K | 82K | 102K | 1.04M | 4.5M | 2.95M | 2M |
| Pretax Income | -6.03M▲ 0% | -16.31M▼ 170.5% | -22.13M▼ 35.7% | -43.51M▼ 96.7% | -55.27M▼ 27.0% | -62.62M▼ 13.3% | -93.4M▼ 49.1% | -32.93M▲ 0% |
| Pretax Margin % | -484.65% | - | - | -15267.72% | -4054.66% | -4019.32% | -6088.4% | -5488.67% |
| Income Tax | 0 | 0 | 0 | 0 | 13K | 59K | 39K | 15K |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | -0.02% | -0.09% | -0.04% | -0.05% |
| Net Income | -6.03M▲ 0% | -16.31M▼ 170.5% | -22.13M▼ 35.7% | -43.51M▼ 96.7% | -55.28M▼ 27.0% | -62.68M▼ 13.4% | -93.44M▼ 49.1% | -32.95M▲ 0% |
| Net Margin % | -484.65% | - | - | -15267.72% | -4055.61% | -4023.11% | -6090.94% | -5491.17% |
| Net Income Growth % | - | -170.46% | -35.7% | -96.65% | -27.04% | -13.39% | -49.07% | 66.25% |
| Net Income (Continuing) | -6.03M | -16.31M | -22.13M | -43.51M | -55.28M | -62.68M | -93.44M | -32.95M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.98▲ 0% | -62.50▼ 6277.6% | -2.59▲ 95.9% | -3.35▼ 29.3% | -1.83▲ 45.4% | -1.26▲ 31.1% | -1.43▼ 13.5% | -18.64▲ 0% |
| EPS Growth % | - | -6277.55% | 95.86% | -29.34% | 45.37% | 31.15% | -13.49% | -508.61% |
| EPS (Basic) | -0.98 | -62.50 | -2.59 | -3.35 | -1.83 | -1.26 | -1.43 | - |
| Diluted Shares Outstanding | 6.27M | 8.18M | 8.59M | 12.99M | 30.24M | 49.8M | 65.11M | 1.77M |
| Basic Shares Outstanding | 6.27M | 8.18M | 8.55M | 12.99M | 30.24M | 49.75M | 65.11M | 1.77M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
LYRA Balance Sheet
Lyra Therapeutics, Inc. (LYRA) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 24.93M | 10.12M | 75.92M | 47.92M | 100.83M | 104.82M | 43.02M | 23.02M |
| Cash & Short-Term Investments | 23.89M | 9.81M | 74.59M | 45.75M | 97.89M | 102.75M | 40.58M | 22.05M |
| Cash Only | 23.89M | 9.81M | 74.59M | 45.75M | 32.55M | 22.35M | 40.58M | 22.05M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 65.34M | 80.4M | 0 | 0 |
| Accounts Receivable | 167K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | 49 | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 2.94M | 2.07M | 2.45M | 964K |
| Total Non-Current Assets | 432K | 4.84M | 4.91M | 6.95M | 9.14M | 37.78M | 23.32M | 20.69M |
| Property, Plant & Equipment | 103K | 3.42M | 4.47M | 5.86M | 4.47M | 35.28M | 21.33M | 18.7M |
| Fixed Asset Turnover | 12.08x | - | - | 0.05x | 0.31x | 0.04x | 0.07x | 0.03x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 329K | 329K | 0 | 0 | 0 | 1.39M | 1.99M | 3.99M |
| Other Non-Current Assets | 0 | 1.1M | 447K | 1.09M | 4.67M | 1.11M | 0 | 3.99M |
| Total Assets | 25.36M▲ 0% | 14.96M▼ 41.0% | 80.83M▲ 440.2% | 54.87M▼ 32.1% | 109.97M▲ 100.4% | 142.6M▲ 29.7% | 66.35M▼ 53.5% | 43.71M▲ 0% |
| Asset Turnover | 0.05x | - | - | 0.01x | 0.01x | 0.01x | 0.02x | 0.01x |
| Asset Growth % | - | -41% | 440.2% | -32.12% | 100.43% | 29.67% | -53.47% | -202.6% |
| Total Current Liabilities | 1.96M | 5.21M | 4.88M | 18.25M | 14.47M | 19.6M | 12.63M | 9.48M |
| Accounts Payable | 631K | 1.07M | 922K | 3.13M | 2.62M | 3.13M | 1.18M | 627K |
| Days Payables Outstanding | - | - | 26.88 | 38.41 | - | - | - | 976.68 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4.68M |
| Deferred Revenue (Current) | 0 | 3.13M | 0 | 9.79M | 1.27M | 1.66M | 398K | 653K |
| Other Current Liabilities | 845K | -3.02M | 149K | 633K | 659K | 1.23M | 6.93M | 4.16M |
| Current Ratio | 12.72x | 1.94x | 15.54x | 2.63x | 6.97x | 5.35x | 3.41x | 3.41x |
| Quick Ratio | 12.72x | 1.94x | 15.54x | 2.63x | 6.97x | 5.35x | 3.41x | 3.41x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 130.47M | 2.43M | 1.45M | 2.31M | 14.74M | 33.58M | 42.12M | 38.56M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 26.7M |
| Capital Lease Obligations | 0 | 2.43M | 1.45M | 379K | 667K | 21.45M | 30.26M | 87.3M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 130.47M | 0 | 0 | 0 | 0 | 0 | 0 | 11.86M |
| Total Liabilities | 132.43M | 7.63M | 6.34M | 20.55M | 29.21M | 53.18M | 54.75M | 48.04M |
| Total Debt | 0 | 3.33M | 2.44M | 1.45M | 4.18M | 26.88M | 34.38M | 31.38M |
| Net Debt | -23.89M | -6.48M | -72.15M | -44.29M | -28.37M | 4.53M | -6.2M | 9.32M |
| Debt / Equity | - | 0.45x | 0.03x | 0.04x | 0.05x | 0.30x | 2.97x | 2.97x |
| Debt / EBITDA | - | - | - | - | - | - | - | -0.91x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | -0.27x |
| Interest Coverage | - | - | - | - | - | - | - | - |
| Total Equity | -107.07M▲ 0% | 7.33M▲ 106.8% | 74.49M▲ 916.5% | 34.32M▼ 53.9% | 80.75M▲ 135.3% | 89.42M▲ 10.7% | 11.59M▼ 87.0% | -4.33M▲ 0% |
| Equity Growth % | - | 106.84% | 916.54% | -53.93% | 135.32% | 10.73% | -87.03% | -397.79% |
| Book Value per Share | -17.09 | 0.90 | 8.67 | 2.64 | 2.67 | 1.80 | 0.18 | -2.45 |
| Total Shareholders' Equity | -107.07M | 7.33M | 74.49M | 34.32M | 80.75M | 89.42M | 11.59M | -4.33M |
| Common Stock | 6K | 6K | 13K | 13K | 32K | 57K | 65K | 2K |
| Retained Earnings | -111.45M | -127.76M | -149.88M | -193.4M | -248.68M | -311.36M | -404.79M | -426.76M |
| Treasury Stock | -4.37M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -2.8M | 0 | 0 | 0 | 10K | 33K | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
LYRA Cash Flow Statement
Lyra Therapeutics, Inc. (LYRA) cash flow — operating, investing & free cash flow history
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -6.64M | -13.75M | -21.14M | -25.82M | -43.38M | -63.3M | -70.01M | -70.01M |
| Operating CF Margin % | -533.76% | - | - | -9059.65% | -3183.05% | -4063.16% | -4563.95% | - |
| Operating CF Growth % | - | -107.14% | -53.72% | -22.12% | -68.03% | -45.91% | -10.59% | 222.7% |
| Net Income | -6.03M | -16.31M | -22.13M | -43.51M | -55.28M | -62.68M | -93.44M | -32.95M |
| Depreciation & Amortization | 82K | 27K | 95K | 1M | 1.07M | 278K | 471K | 506K |
| Stock-Based Compensation | 406K | 244K | 1.81M | 2.77M | 5.45M | 5.89M | 6.72M | 3.68M |
| Deferred Taxes | 0 | 0 | 0 | -2.42M | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -1.18M | 167K | -45K | 2.42M | 824K | -1.9M | 22.58M | -237K |
| Working Capital Changes | 79K | 2.11M | -879K | 13.92M | 4.55M | -4.88M | -6.35M | -5.14M |
| Change in Receivables | 164K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 134K | -205K | 345K | 2.35M | -2.41M | 450K | -1.89M | -1.73M |
| Cash from Investing | -37K | -211K | -1.77M | -3.38M | -65.01M | -12.58M | 80.31M | 28.13M |
| Capital Expenditures | -37K | -211K | -1.77M | -3.38M | -164K | -1.05M | -2.34M | 38K |
| CapEx % of Revenue | 2.97% | - | - | 1187.72% | 12.03% | 67.2% | 152.41% | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 18K |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 29.21M | -115K | 87.7M | 359K | 96.26M | 65.69M | 8.53M | 4.27M |
| Debt Issued (Net) | 500K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 0 | 111K | 1000K | 604K | 1000K | 1000K | 1000K | 999K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 28.71M | -226K | -2.58M | -245K | -4.24M | -3.55M | -287K | -726K |
| Net Change in Cash | 22.54M▲ 0% | -14.08M▼ 162.5% | 64.78M▲ 560.1% | -28.85M▼ 144.5% | -12.13M▲ 57.9% | -10.2M▲ 16.0% | 18.82M▲ 284.6% | -1.74M▲ 0% |
| Free Cash Flow | -6.68M▲ 0% | -13.96M▼ 109.2% | -22.92M▼ 64.1% | -29.2M▼ 27.4% | -43.55M▼ 49.1% | -64.35M▼ 47.8% | -72.35M▼ 12.4% | -34.11M▲ 0% |
| FCF Margin % | -536.74% | - | - | -10247.37% | -3195.08% | -4130.36% | -4716.36% | -5684.5% |
| FCF Growth % | - | -109.15% | -64.11% | -27.43% | -49.11% | -47.77% | -12.43% | 57.84% |
| FCF per Share | -1.07 | -1.71 | -2.67 | -2.25 | -1.44 | -1.29 | -1.11 | -1.11 |
| FCF Conversion (FCF/Net Income) | 1.10x | 0.84x | 0.96x | 0.59x | 0.78x | 1.01x | 0.75x | 1.04x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
LYRA Key Ratios
Lyra Therapeutics, Inc. (LYRA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -222.52% | -54.09% | -79.98% | -96.08% | -73.67% | -184.99% | -1032.82% |
| Return on Invested Capital (ROIC) | - | -1046.28% | - | -199.18% | -68.8% | -145.47% | -145.47% |
| Gross Margin | - | - | -10318.95% | 100% | 100% | 100% | 50% |
| Net Margin | - | - | -15267.72% | -4055.61% | -4023.11% | -6090.94% | -5491.17% |
| Debt / Equity | 0.45x | 0.03x | 0.04x | 0.05x | 0.30x | 2.97x | 2.97x |
| FCF Conversion | 0.84x | 0.96x | 0.59x | 0.78x | 1.01x | 0.75x | 1.04x |
| Revenue Growth | -100% | - | - | 378.25% | 14.31% | -1.54% | -59.21% |
LYRA Frequently Asked Questions
Lyra Therapeutics, Inc. (LYRA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Lyra Therapeutics, Inc. (LYRA) reported $0.6M in revenue for fiscal year 2024. This represents a 52% decrease from $1.2M in 2018.
Lyra Therapeutics, Inc. (LYRA) saw revenue decline by 1.5% over the past year.
Lyra Therapeutics, Inc. (LYRA) reported a net loss of $32.9M for fiscal year 2024.
Dividend & Returns
Lyra Therapeutics, Inc. (LYRA) has a return on equity (ROE) of -185.0%. Negative ROE indicates the company is unprofitable.
Lyra Therapeutics, Inc. (LYRA) had negative free cash flow of $34.1M in fiscal year 2024, likely due to heavy capital investments.
Explore More LYRA
Lyra Therapeutics, Inc. (LYRA) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates